Tango Therapeutics, Inc. (NasdaqGM: TNGX)
Health Care · Biotechnology · US
$22.57
-2.88% today · +206.6% 1Y
Tango Therapeutics, Inc. (NasdaqGM: TNGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.92B and employs 137 people.
Over the last twelve months the share price has gained 206.6%, trading between 6.69 and 34.39.
Tweenvest scores Tango Therapeutics, Inc. across four factors: quality 42/100, value 70/100, growth 100/100. Its strongest factor is growth.
TNGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.92B
- Revenue (TTM)
- $53.81M
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- $34.39
- 52-week low
- $6.69
- Avg volume (3M)
- —
- Shares outstanding
- 168.61M
- Employees
- 137
- Next earnings
- —
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
- ISIN
- US87583X1090
- Founded
- 2017
- Listed since
- Sep 3, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.27B | CN¥95.00 | +3.34% |
| Shanghai Henlius Biotech, Inc.SEHK: 2696 | $4.06B | HK$58.40 | +2.10% |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd.SHSE: 688192 | $4.02B | CN¥58.01 | +2.76% |
| Relay Therapeutics, Inc.NasdaqGM: RLAY | $3.93B | $17.41 | -3.01% |
| Telix Pharmaceuticals LimitedASX: TLX | $3.75B | AU$15.87 | +2.99% |
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.71B | CN¥12.59 | +4.05% |
| Legend Biotech CorporationNasdaqGS: LEGN | $3.70B | $18.71 | -2.14% |
| Xenon Pharmaceuticals Inc.NasdaqGM: XENE | $3.68B | $36.16 | -4.89% |
Figures last refreshed Oct 4, 2026.